Raymond James Financial Inc. Purchases Shares of 41,592 Integra LifeSciences Holdings Co. (NASDAQ:IART)

Raymond James Financial Inc. purchased a new position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 41,592 shares of the life sciences company's stock, valued at approximately $943,000. Raymond James Financial Inc. owned about 0.05% of Integra LifeSciences at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Charles Schwab Investment Management Inc. increased its stake in Integra LifeSciences by 10.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,047,573 shares of the life sciences company's stock valued at $23,759,000 after buying an additional 103,291 shares during the period. Principal Financial Group Inc. increased its stake in shares of Integra LifeSciences by 5.5% during the fourth quarter. Principal Financial Group Inc. now owns 423,432 shares of the life sciences company's stock worth $9,603,000 after acquiring an additional 22,000 shares during the period. Leeward Investments LLC MA raised its holdings in Integra LifeSciences by 7.8% during the fourth quarter. Leeward Investments LLC MA now owns 405,506 shares of the life sciences company's stock worth $9,197,000 after purchasing an additional 29,402 shares in the last quarter. Norges Bank acquired a new stake in Integra LifeSciences in the fourth quarter valued at about $8,967,000. Finally, JPMorgan Chase & Co. boosted its holdings in Integra LifeSciences by 130.5% in the 4th quarter. JPMorgan Chase & Co. now owns 199,691 shares of the life sciences company's stock valued at $4,529,000 after purchasing an additional 113,061 shares in the last quarter. 84.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on IART shares. JPMorgan Chase & Co. cut their target price on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research note on Tuesday. Truist Financial cut their price objective on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. JMP Securities cut their price target on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a report on Friday. Finally, Wells Fargo & Company lowered their target price on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Tuesday. Four equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $18.63.

Integra LifeSciences Price Performance

Shares of IART stock traded down $0.64 during trading hours on Friday, hitting $12.25. The company's stock had a trading volume of 1,542,604 shares, compared to its average volume of 1,038,904. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The business has a fifty day moving average of $18.93 and a 200-day moving average of $21.87. Integra LifeSciences Holdings Co. has a twelve month low of $11.60 and a twelve month high of $32.66. The stock has a market cap of $951.97 million, a price-to-earnings ratio of -136.10, a P/E/G ratio of 0.73 and a beta of 1.27.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its earnings results on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $382.65 million for the quarter, compared to analyst estimates of $381.17 million. During the same quarter last year, the company posted $0.55 EPS. Integra LifeSciences's quarterly revenue was up 3.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.